Chen Dewei, Gao Wenxiang, Wang Shouxian, Ni Bing, Gao Yuqi
Department of Pathophysiology and High Altitude Pathology, College of High Altitude Military Medicine, Third Military Medical University, Chongqing, People's Republic of China.
Key Laboratory of High Altitude Medicine of PLA, College of High Altitude Military Medicine, Third Military Medical University, Chongqing, 400038, People's Republic of China.
Cell Mol Life Sci. 2017 Oct;74(20):3789-3808. doi: 10.1007/s00018-017-2551-8. Epub 2017 Jun 1.
Pulmonary arterial hypertension (PAH) is characterized by persistent pulmonary vasoconstriction and pulmonary vascular remodeling. The pathogenic mechanisms of PAH remain to be fully clarified and measures of effective prevention are lacking. Recent studies; however, have indicated that epigenetic processes may exert pivotal influences on PAH pathogenesis. In this review, we summarize the latest research findings regarding epigenetic regulation in PAH, focusing on the roles of non-coding RNAs, histone modifications, ATP-dependent chromatin remodeling and DNA methylation, and discuss the potential of epigenetic-based therapies for PAH.
肺动脉高压(PAH)的特征是持续性肺血管收缩和肺血管重塑。PAH的发病机制仍有待充分阐明,且缺乏有效的预防措施。然而,最近的研究表明,表观遗传过程可能对PAH的发病机制产生关键影响。在本综述中,我们总结了关于PAH表观遗传调控的最新研究发现,重点关注非编码RNA、组蛋白修饰、ATP依赖的染色质重塑和DNA甲基化的作用,并讨论基于表观遗传学的PAH治疗潜力。